Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
34.3 CHF | -3.11% | -2.83% | -31.26% |
04-23 | Xlife Sciences Posts Higher FY23 Profit; Revenue Falls | MT |
02-29 | Xlife Sciences AG Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
Fiscal Period: December | 2022 | 2023 | 2024 |
---|---|---|---|
Capitalization 1 | 156.9 | 279 | 201.9 |
Enterprise Value (EV) 1 | 216.9 | 335.2 | 267.1 |
P/E ratio | 14.9 x | 24 x | -53.6 x |
Yield | - | - | - |
Capitalization / Revenue | 153 x | 282 x | 252 x |
EV / Revenue | 211 x | 339 x | 334 x |
EV / EBITDA | -43.7 x | -78.4 x | -66.8 x |
EV / FCF | -46.3 x | - | -53.4 x |
FCF Yield | -2.16% | - | -1.87% |
Price to Book | - | - | - |
Nbr of stocks (in thousands) | 5,284 | 5,590 | 5,703 |
Reference price 2 | 29.70 | 49.90 | 35.40 |
Announcement Date | 20/04/23 | 29/02/24 | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|
Net sales 1 | 0.3968 | 0.8061 | 1.028 | 0.9884 | 0.8 |
EBITDA 1 | -2.964 | - | -4.961 | -4.278 | -4 |
EBIT 1 | -3.025 | - | -20.98 | -20.31 | -4.19 |
Operating Margin | -762.31% | - | -2,041.2% | -2,054.54% | -523.75% |
Earnings before Tax (EBT) 1 | 21.26 | - | 4.039 | 4.534 | -5 |
Net income 1 | 21.62 | 53.42 | 14.31 | 14.88 | -4 |
Net margin | 5,449.53% | 6,627.03% | 1,392.26% | 1,505.33% | -500% |
EPS 2 | - | - | 2.000 | 2.080 | -0.6600 |
Free Cash Flow 1 | -0.4577 | - | -4.688 | - | -5 |
FCF margin | -115.35% | - | -456.01% | - | -625% |
FCF Conversion (EBITDA) | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - |
Dividend per Share | - | - | - | - | - |
Announcement Date | 31/03/21 | 29/04/22 | 20/04/23 | 29/02/24 | - |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|
Net Debt 1 | 50.8 | - | 60 | 56.2 | 65.2 |
Net Cash position 1 | - | - | - | - | - |
Leverage (Debt/EBITDA) | -17.15 x | - | -12.1 x | -13.14 x | -16.3 x |
Free Cash Flow 1 | -0.46 | - | -4.69 | - | -5 |
ROE (net income / shareholders' equity) | 19% | - | - | - | - |
ROA (Net income/ Total Assets) | 12.7% | - | - | - | - |
Assets 1 | 169.9 | - | - | - | - |
Book Value Per Share | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - |
Capex 1 | - | - | 0.08 | - | 1 |
Capex / Sales | - | - | 7.8% | - | 125% |
Announcement Date | 31/03/21 | 29/04/22 | 20/04/23 | 29/02/24 | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-31.26% | 224M | |
+33.40% | 49.46B | |
+1.63% | 42.58B | |
+49.11% | 42.49B | |
-4.22% | 29.09B | |
+11.60% | 26.61B | |
-22.78% | 18.64B | |
+8.09% | 13.16B | |
+29.19% | 12.55B | |
+24.33% | 12.1B |
- Stock Market
- Equities
- XLS Stock
- Financials Xlife Sciences AG